250 related articles for article (PubMed ID: 15149548)
1. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors.
Koul S; McKiernan JM; Narayan G; Houldsworth J; Bacik J; Dobrzynski DL; Assaad AM; Mansukhani M; Reuter VE; Bosl GJ; Chaganti RS; Murty VV
Mol Cancer; 2004 May; 3():16. PubMed ID: 15149548
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells.
Ma LC; Kuo CC; Liu JF; Chen LT; Chang JY
Mol Pharmacol; 2008 Aug; 74(2):517-26. PubMed ID: 18492797
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin represses transcriptional activity from the minimal promoter of the O6-methylguanine methyltransferase gene and increases sensitivity of human gallbladder cancer cells to 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-2-chloroethyl)-3-nitrosourea.
Sato K; Kitajima Y; Nakagawachi T; Soejima H; Miyoshi A; Koga Y; Miyazaki K
Oncol Rep; 2005 May; 13(5):899-906. PubMed ID: 15809756
[TBL] [Abstract][Full Text] [Related]
4. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance.
Wermann H; Stoop H; Gillis AJ; Honecker F; van Gurp RJ; Ammerpohl O; Richter J; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Pathol; 2010 Aug; 221(4):433-42. PubMed ID: 20593487
[TBL] [Abstract][Full Text] [Related]
5. Alterations in S-adenosylhomocysteine metabolism decrease O6-methylguanine DNA methyltransferase gene expression without affecting promoter methylation.
Hermes M; Geisler H; Osswald H; Riehle R; Kloor D
Biochem Pharmacol; 2008 Jun; 75(11):2100-11. PubMed ID: 18395186
[TBL] [Abstract][Full Text] [Related]
6. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
7. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin.
Dhillon VS; Shahid M; Husain SA
Mol Cancer; 2004 Dec; 3():33. PubMed ID: 15574200
[TBL] [Abstract][Full Text] [Related]
8. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
[TBL] [Abstract][Full Text] [Related]
9. Characteristic promoter hypermethylation signatures in male germ cell tumors.
Koul S; Houldsworth J; Mansukhani MM; Donadio A; McKiernan JM; Reuter VE; Bosl GJ; Chaganti RS; Murty VV
Mol Cancer; 2002 Nov; 1():8. PubMed ID: 12495446
[TBL] [Abstract][Full Text] [Related]
10. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix.
Dong SM; Kim HS; Rha SH; Sidransky D
Clin Cancer Res; 2001 Jul; 7(7):1982-6. PubMed ID: 11448914
[TBL] [Abstract][Full Text] [Related]
12. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
[TBL] [Abstract][Full Text] [Related]
13. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line.
Spierings DC; de Vries EG; Vellenga E; de Jong S
Cell Death Differ; 2003 Jul; 10(7):808-22. PubMed ID: 12815464
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis.
Esteller M; Risques RA; Toyota M; Capella G; Moreno V; Peinado MA; Baylin SB; Herman JG
Cancer Res; 2001 Jun; 61(12):4689-92. PubMed ID: 11406538
[TBL] [Abstract][Full Text] [Related]
15. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.
Zhao W; Soejima H; Higashimoto K; Nakagawachi T; Urano T; Kudo S; Matsukura S; Matsuo S; Joh K; Mukai T
J Biochem; 2005 Mar; 137(3):431-40. PubMed ID: 15809347
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
[TBL] [Abstract][Full Text] [Related]
17. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
Bai T; Tanaka T; Yukawa K; Umesaki N
Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
[TBL] [Abstract][Full Text] [Related]
18. MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma.
Choy KW; Lee TC; Cheung KF; Fan DS; Lo KW; Beaverson KL; Abramson DH; Lam DS; Yu CB; Pang CP
Neoplasia; 2005 Mar; 7(3):200-6. PubMed ID: 15799820
[TBL] [Abstract][Full Text] [Related]
20. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.
Wolf P; Hu YC; Doffek K; Sidransky D; Ahrendt SA
Cancer Res; 2001 Nov; 61(22):8113-7. PubMed ID: 11719438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
